Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 36

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 36
---
11,750- 51 - 51  Exercise of options -- -- -- 88,500- 266 - 266  Exercise of warrants -- -- -- 24,313- 55 - 55  Stock-based compensation expense -- -- -- -- 3,073 - 3,073  Net loss -- -- -- -- - (16,268)(16,268)Balances at December 31, 2024-$- -$- -$- 15,122,873$2 $69,699 $(66,783)$2,918 

The accompanying notes are an integral part of these financial statements.

F-5

INTENSITY THERAPEUTICS, INC.

STATEMENTS OF CASH FLOWS

(in thousands)

Years Ended December 31,20242023Cash flows from operating activities:Net loss$(16,268)$(10,538)Adjustments to reconcile net loss to net cash used in operating activities:Amortization of discount on convertible notes- 159 Change in carrying value of right-of-use asset25 147 Stock-based compensation expense3,073 1,398 Stock issued in exchange for services51 - Loss on debt extinguishment- 2,262 Changes in operating assets and liabilities, net:Accrued interest on marketable debt securities(134)(197)Prepaid expenses, other current assets, and other assets301 (2,067)Accounts payable, accrued expenses and other liabilities(2,268)1,631 Net cash used in operating activities(15,220)(7,205)Cash flows from investing activities:Purchase of marketable debt securities(3,056)(15,053)Redemption of marketable debt securities9,410 9,030 Net cash provided by (used in) investing activities6,354 (6,023)Cash flows from financing activities:Proceeds from Registered Direct Offering3,000 - Issuance costs related to Registered Direct Offering(571)- Proceeds from ATM offering232 - Issuance costs related to ATM offering(82)- Proceeds from Initial Public Offering and overallotment- 22,425 Issuance costs related to Initial Public Offering and overallotment- (2,233)Proceeds from issuance of convertible note- 230 Proceeds from exercise of options and warrants